Bivalirudin as an anticoagulation agent: Safety and efficacy in peripheral interventions

Journal of Vascular and Interventional Radiology

Volumn 16, Issue 9, 2005, Pages 1183-1187

  Katzen, Barry T ^a   Ardid, Maria I ^a   MacLean, Alexandra A ^a   Kovacs, Margaret F ^a   Zemel, Gerald ^a   Benenati, James F ^a   Powell, Alex ^a   Samuels, Shaun ^a  

^a BAPTIST CARDIAC AND VASCULAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN; HIRULOG;

ADULT; AGED; AMPUTATION; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CONTROLLED STUDY; DEBRIDEMENT; DRUG EFFICACY; DRUG SAFETY; EMBOLISM; FEMALE; HEMATOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REVASCULARIZATION; THROMBOSIS;

EID: 24944532983     PISSN: 10510443     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.RVI.0000171694.01237.26     Document Type: Article

References (21)

1. Gruntzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med 1979; 301:61-68.
2. Chew DP, Bhatt DL, Lincoff AM, et al. Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials. Circulation 2001; 103:961-966.
3. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:1885-2035.
4. Levine MN, Raskob G, Beyth RJ, Kearon C, Schulman S. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:287S-310S.
5. Kong DF, Topol EJ, Bittl JA, White HD, Theroux P, Hasselblad V, Califf RM. Clinical outcomes of bivalirudin for ischemic heart disease. Circulation 1999; 100:2049-2053.
6. Bovill EG, Tracy RP, Knatterud GE, et al. Hemorrhagic events during therapy with recombinant tissue plasminogen activator, heparin, and aspirin for unstable angina (Thrombolysis in Myocardial Ischemia, phase IIIB trial). Am J Cardiol 1997; 79:391-396.
7. Eikelboom J, White H, Yusuf S. The evolving rule of direct thrombin inhibitors in acute coronary syndromes. J Am Coll Cardiol 2003; 41:70S-78S.
8. Antman EM, McCabe CH, Braunwald E. Bivalirudin as a replacement for unfractionated heparin in unstable angina/non-ST-elevation myocardial infarction: observations from the TIMI 8 trial. The Thrombolysis in Myocardial Infarction. Am Heart J 2002; 143:229-234.
9. Lincoff AM, Bittl JA, Kleiman NS, et al. Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial). Am J Cardiol 2004; 93:1092-1096.
10. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003; 289:853-863.
11. Weitz JI, Crowther MA. New anticoagulants: current status and future potential. Am J Cardiovasc Drugs 2003; 3:201-209.
12. Weitz JI, Hirsh J, Samama MM. New anticoagulant drugs: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:2655-2865.
13. Allie DE, Lirtzman MD, Wyatt CH, et al. Bivalirudin as a foundation anticoagulant in peripheral vascular disease: a safe and feasible alternative for renal and iliac interventions. J Invasive Cardiol 2003; 15:334-342.
14. Ormiston JA, Shaw BE, Panther MJ, et al. Percutaneous coronary intervention with bivalirudin anticoagulation, immediate sheath removal, and early ambulation: a feasibility study with implications for day-stay procedures. Catheter Cardiovasc Interv 2002; 55:289-293.
15. Sacks D, Marinelli DE, Martin EG, Spies JB. Reporting standards for clinical evaluation of new peripheral arterial revascularization devices. J Vasc Interv Radiol 2003; 14:5395-404.
16. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:3115-3375.
17. Cohen DJ, Lincoff AM, Lavelle TA, et al. Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial. J Am Coll Cardiol 2004; 44:1792-1800.
18. Warkentin TE, Sheppard JA, Horsewood P, Simpson PJ, Moore JC, Kelton JG. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 2000; 96:1703-1708.
19. Bittl JA, Chaitman BR, Feit F, Kimball W, Topol EJ. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J 2001; 142: 952-959.
20. Lincoff AM, Kleiman NS, Kottke-Marchant K, et al. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET). Am Heart J 2002; 143:847-853.
21. Shammas NW, Lemke JH, Dippel EJ, et al. Bivalirudin in peripheral vascular interventions: a single center experience. J Invasive Cardiol 2003; 15:401-404.